Lifeward (formerly ReWalk Robotics)

Lifeward operates across rehabilitation robotics and mobility devices, with a portfolio spanning personal exoskeletons, stroke-rehabilitation equipment, functional electrical stimulation cycling, and anti-gravity treadmill systems. In personal exoskeletons, Ekso Bionics is a relevant competitor, while Wandercraft is another company developing robotic walking systems; both address adjacent mobility and rehabilitation needs. Lifeward’s ReWalk Personal Exoskeleton is differentiated by its focus on personal use for people with spinal cord injuries, including standing, walking, turning, and stair or curb navigation. Its ReStore Exo-Suit targets gait training after stroke, while the acquired AlterG line adds pressurized-air anti-gravity systems for rehabilitation and training. That broader product mix gives Lifeward exposure to both clinical rehabilitation settings and individual mobility. Distribution and access partnerships are strategically important in this category: the 2026 Ottobock Care pilot aims to use an established U.S. care network, while prior agreements extended product availability across Germany and several international markets. Lifeward is a public company trading as NASDAQ:RWLK, rather than an early-stage private venture. Its competitive position depends not only on device capabilities, but also on clinical adoption, reimbursement, and the reach of its care and distribution partners.

Lifeward’s trajectory reflects a transition from a focused exoskeleton developer toward a broader rehabilitation-technology company. Founded in 2001 and public since 2014, it has accumulated 21 reported funding rounds and $270.82 million in total funding. A major portfolio expansion came with its 2023 acquisition of AlterG for $19 million, adding anti-gravity treadmill systems alongside ReWalk exoskeletons and the ReStore Exo-Suit. Product commercialization has continued with the U.S. launch of ReWalk 7 in April 2025, followed by reported installations and customer feedback later that year. Partnerships have supported a parallel access strategy: agreements expanded distribution in the Gulf region and in Mexico, Thailand, and the UAE, while the 2026 Ottobock Care pilot focuses on U.S. patient access. Financing remains an important part of the operating picture: the company raised $27 million in post-IPO equity and $20 million in post-IPO debt in January 2026, and $5.6 million in post-IPO debt in July. These milestones coexist with headcount and leadership uncertainty: the company is listed in the 51–100 employee range, a layoff event was recorded in March 2025, and interim CEO and CFO appointments followed in September 2026. Execution will hinge on converting distribution, reimbursement, and product adoption into sustained commercial scale.